BioSpace· Heather McKenzie·· 4 hours agoPickScore73
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
In brief
AbbVie presented Phase 2a TARGET-CD data as a late-breaker at the 2026 UEGW congress: ABBV-466, a Crohn's combination therapy pairing Skyrizi with the anti-alpha-4-beta-7 integrin antibody trosunilimab, achieved higher endoscopic remission rates than either monotherapy group, meeting the primary endpoint.
Why it matters
Phase 2a provides week 12 and week 24 endoscopic remission figures for direct comparison against Skyrizi monotherapy, showing AbbVie's combo lifecycle strategy in IBD.
Source: BioSpace